Abrégé

An antisense oligonucleotides having the ability to decrease the expression level of the huntingtin protein in glioma cells, for their use in sensitizing the cells to an anti-cancer treatment.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
• A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
• A61K 31/282 - Composés du platine
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61P 35/00 - Agents anticancéreux

Abrégé

In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during the bradyzoite stage of the parasite. In cysts directly purified from the brain of mice, the protein is distributed within and at the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptides and a recombinantly expressed c-terminal domain (rBCLA) constitutes an efficient serological marker of latent infection with a high sensitivity that is clearly and exclusively correlated with the presence of cysts in the brain of mice Antibodies directed against BCLA antigen have been detected in human patients with enriched titers in patients qualified as seropositive to Sag1 or tachyzoite related antigens. Further correlation in humans between anti-BCLA IgG synthesis and cysts is brought by significantly stronger recorded titers in pathological panels strongly related to the presence of cyst. Furthermore, newborn infants with a confirmed congenital toxoplasmosis display significantly higher anti-BCLA IgGs at birth when compared to their mother, suggesting a specific in-utero neosynthesis of such IgGs. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BCLA, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite/cyst). This specific protein and its antigenic fragments can be used to detect autoantibodies in the sera of patient for the diagnosis of the latent form of Toxoplasmosis. The invention also relates to derived antibodies, generated by BCLA immunisation that specifically binds this new protein.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to a nanostructured biomimetic neuromorphic system including a solution comprising inverted micelles (14) in contact with each other so as to form lipid bilayers (13) at contact points, at least part of said contact points comprising at least one ion transporting membrane protein (15) allowing at least one ion transport from an inverted micelle (14) to another in return for a reverse exchange of at least one ion, wherein said solution comprising inverted micelles (14) is a compacted emulsion (10). Such system permits the creation of an ionic gradient that permits to generate a voltage.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• H01M 14/00 - Générateurs électrochimiques de courant ou de tension non prévus dans les groupes Leur fabrication
• A61B 5/388 - Études de la conduction nerveuse, p. ex. détection du potentiel d’action d’un nerf périphérique

Abrégé

The invention relates to antisense oligonucleotides having the ability to reduce the expression level of the huntingtin protein in glioma cells, for use thereof in sensitizing said cells to cancer treatment.

Classes IPC  ?

• A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
• A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
• A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61N 5/00 - Thérapie par radiations
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to antisense oligonucleotides having the ability to reduce the expression level of the huntingtin protein in glioma cells, for use thereof in sensitizing said cells to cancer treatment.

Classes IPC  ?

• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61P 35/00 - Agents anticancéreux
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61N 5/00 - Thérapie par radiations
• A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
• A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
• A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol

Abrégé

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

Classes IPC  ?

• A61K 51/06 - Composés macromoléculaires
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
• A61K 49/12 - Composés macromoléculaires
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61P 35/00 - Agents anticancéreux

Abrégé

Microvascular dysfunction remains a major contributor to the development of skin complications. The inventors assessed the impact of the local inhibition of soluble epoxide hydrolase (sEH), which metabolizes vasodilator and anti-inflammatory epoxyeicosanoids, on the diabetic skin microvascular dysfunction. The inventors have therefore developed some formulations of sEH inhibitors (GSK2256294 and t-AUCB) for topical administration. In particular, they show that an aqueous gel containing 400 mg/L t-AUCB dissolved in 50% dimethy lsulfo xide (DMSO) allowed a stable and continuous diffusion of t-AUCB from 2 hours after application on skin pig ears to over a period of 24 h. Compared to a control gel, the gel with t-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.

Classes IPC  ?

• A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

A support for a biological species sample collected on a sampling device including a gripping rod and a capture element having a capture surface for receiving the sample. The capture element being assembled with the gripping rod in order to form a distal portion of the sampling device. The support has a flat main face delimited by at least one side and a recess opening on the side of the support in which the sampling device can be inserted. The recess has a groove formed on the main face of the support in order to receive the distal portion of the sampling device. The groove being configured to interact with the distal portion in order to securely hold it on or in the support.

Classes IPC  ?

• A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during the bradyzoite stage of the parasite. In cysts directly purified from the brain of mice, the protein is distributed within and at the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptides and a recombinantly expressed c-terminal domain (rBCLA) constitutes an efficient serological marker of latent infection with a high sensitivity that is clearly and exclusively correlated with the presence of cysts in the brain of mice. Antibodies directed against BCLA antigen have been detected in human patients with enriched titers in patients qualified as seropositive to Sag1 or tachyzoite related antigens. Further correlation in humans between anti-BCLA IgG synthesis and cysts is brought by significantly stronger recorded titers in pathological panels strongly related to the presence of cyst. Furthermore, newborn infants with a confirmed congenital toxoplasmosis display significantly higher anti-BCLA IgGs at birth when compared to their mother, suggesting a specific in-utero neosynthesis of such IgGs. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BCLA, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite/cyst). This specific protein and its antigenic fragments can be used to detect autoantibodies in the sera of patient for the diagnosis of the latent form of Toxoplasmosis. The invention also relates to derived antibodies, generated by BCLA immunisation that specifically binds this new protein.

Classes IPC  ?

• C07K 14/45 - Toxoplasma

Abrégé

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61P 35/00 - Agents anticancéreux
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between (2) and (7) days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between (1) hour to (12) hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than (40) and said nanoparticles have a mean hydrodynamic diameter below (10) nm.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61P 35/00 - Agents anticancéreux
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
• A61P 35/00 - Agents anticancéreux

Abrégé

ttttt-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.

Classes IPC  ?

• A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
• A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/415 - 1,2-Diazoles
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The invention relates to a method for estimating the attentional resources invoked for execution of a primary task and/or attention sharing strategies developed by an individual, said method being implemented in a mobile terminal, being based on utilization of the dual-task paradigm, and comprising the following steps: Evaluation of first performance ratings of the individual during the execution of a primary task alone, Evaluation of second performance ratings of the individual during the execution of a secondary task alone, Evaluation of third performance ratings of the individual during the simultaneous execution of the primary and secondary tasks, Estimation of the attentional demand required for the execution of the primary task and/or of the effect (beneficial or negative) of a secondary task on the control mechanisms involved in the execution of the primary task and/or attention sharing strategies developed by an individual by comparing the first, second, and third performance ratings.

Classes IPC  ?

• G09B 19/00 - Enseignement non couvert par d'autres groupes principaux de la présente sous-classe
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
• G09B 7/02 - Dispositifs ou appareils d'enseignement à commande électrique procédant par questions et réponses du type où l'élève doit donner une réponse à la question posée, ou bien où la machine donne une réponse à la question posée par l'élève
• G09B 7/00 - Dispositifs ou appareils d'enseignement à commande électrique procédant par questions et réponses
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

Mesothelin (MSLN) has been found to be overexpressed in several human malignancies: 100% of epithelial mesotheliomas, the majority of pancreatic and ovarian adenocarcinomas, more than 50 % of lung adenocarcinomas and 34 to 67 % of triple negative breast cancer (TNBC). The limited expression of mesothelin in normal human tissues and its overexpression in several aggressive human cancers make MSLN an attractive candidate for therapy. The objective of the inventors was to perform the nuclear imaging of TNBC xenografts with anti-MSLN single domain antibodies radiolabeled with 99mTc (99mTc-A1 and 99mTc-C6). They showed that 99mTc-A1 represent a good candidate for targeting mesothelin positive tumors. Accordingly, the present invention to an anti-mesothelin single domain antibody which is labelled with a radionuclide and its uses for imaging and/or treating cancer.

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux

Abrégé

A device for acclimatising at altitude comprising a breathing mask defining a confined air space when it is placed on the face of a user. The mask comprising a suction valve to let the surrounding air enter inside the confined space when breathing in; an expiration valve to let air exit with a determined resistance, so as to create an overpressurisation of air in the confined space, when breathing out; and a sensor to establish information about the pressure of the confined space behind. The acclimatisation device in addition comprises a unit for processing the pressure information configured to establish a breathing characteristic of the user and compare it to at least one target value, in view of recommending to them an adjustment of the breathing mode thereof. A method for functioning this device is also provided.

Classes IPC  ?

• A63B 23/18 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour améliorer la fonction respiratoire
• A63B 71/06 - Dispositifs indicateurs ou de marque pour jeux ou joueurs
• A63B 24/00 - Commandes électriques ou électroniques pour les appareils d'exercice des groupes
• A61M 16/06 - Masques respiratoires ou pour l'anesthésie
• A61M 16/20 - Valves spécialement adaptées aux dispositifs respiratoires médicaux
• A63B 21/008 - Appareils de gymnastique pour développer ou fortifier les muscles ou les articulations du corps en surmontant des résistances, avec ou sans dispositifs de mesure utilisant des dispositifs résistants hydrauliques ou pneumatiques
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux
• A61M 16/08 - SouffletsTubes de connection

Abrégé

The invention relates to a support (6) for a biological species sample collected on a sampling device comprising a gripping rod (2) and a capture element (3) having a capture surface (3a) for receiving the sample, the capture element being assembled with the gripping rod (2) in order to form a distal portion of the sampling device. The support (6) has a flat main face (6a) delimited by at least one side and a recess opening on the side of the support (6) in which the sampling device can be inserted. According to the invention, the recess consists of a groove (7) formed on the main face (6a) of the support (6) in order to receive the distal portion of the sampling device, the groove (7) being configured to interact with the distal portion in order to securely hold it on or in the support (6).

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

The invention relates to a method for estimating the attentional resources invoked for the execution of a primary task and/or attention sharing strategies developed by an individual, said method being implemented in a mobile terminal and being based on the utilization of the dual-task paradigm, noteworthy in that it comprises the following steps: - Evaluation (10) of first performance ratings of the individual during the execution of a primary task alone, - Evaluation (20) of second performance ratings of the individual during the execution of a secondary task alone, - Evaluation (30) of third performance ratings of the individual during the simultaneous execution of the primary and secondary tasks, - Estimation (40) of the attentional demand required for the execution of the primary task and/or of the effect (beneficial or negative) of a secondary task on the control mechanisms involved in the execution of the primary task and/or attention sharing strategies developed by an individual by comparing the first, second and third performance ratings evaluated during the previous steps.

Classes IPC  ?

• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G09B 7/00 - Dispositifs ou appareils d'enseignement à commande électrique procédant par questions et réponses
• G09B 19/00 - Enseignement non couvert par d'autres groupes principaux de la présente sous-classe

Abrégé

The invention relates to an altitude acclimatisation device (1) comprising a breathing mask (2) defining a confined air space when it is placed on the face of a user, the mask (2) comprising an inhalation valve (4a) for letting surrounding air into the confined space during inhalation; an exhalation valve for letting air out with a determined resistance in such a way as to create positive air pressure in the confined space during exhalation; and a sensor (5) for establishing pressure information about the rear confined space. The acclimatisation device (1) also comprises a unit for processing the pressure information, designed to establish a breathing characeristic of the user and to compare it with at least one target value, so as to be able to advise the user on adjustment of his or her breathing pattern. The invention also relates to a method for operating said device.

Classes IPC  ?

• A63B 23/18 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour améliorer la fonction respiratoire
• A63B 24/00 - Commandes électriques ou électroniques pour les appareils d'exercice des groupes
• A63B 71/06 - Dispositifs indicateurs ou de marque pour jeux ou joueurs
• A63B 21/008 - Appareils de gymnastique pour développer ou fortifier les muscles ou les articulations du corps en surmontant des résistances, avec ou sans dispositifs de mesure utilisant des dispositifs résistants hydrauliques ou pneumatiques
• A61M 16/08 - SouffletsTubes de connection

Abrégé

The invention relates to an X-ray imaging device including a rotary collimator having a region (22) which is opaque to X-rays, a first slot (24) and a second slot (26), which are transparent to X-rays and extend in two different directions, passing through said opaque region, the collimator making it possible to determine the position of an element provided with X-ray sensors in an imaging system.

Classes IPC  ?

• G01T 7/00 - Détails des instruments de mesure des radiations
• G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
• A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
• A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
• G01T 1/164 - Scintigraphie

Abrégé

The present invention relates to methods for amplifying and sequencing the full-length genome of a hepatitis C vims. The present invention also relates to primers and kits for amplifying and sequencing the full-length genome of a hepatitis C virus.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The present invention relates to methods for amplifying and sequencing the full-length genome of a hepatitis C virus. The present invention also relates to primers and kits for amplifying and sequencing the full-length genome of a hepatitis C virus.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to a method for determining the degree of sensitivity of a strain of fungus to an antifungal agent.

Classes IPC  ?

• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau

Abrégé

The invention relates to a method for determining the degree of sensitivity of a strain of fungus to an antifungal agent.

Classes IPC  ?

• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau

Abrégé

The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient, said method comprising the following steps: a) mixing the undiluted biological sample with tissue factor or a mixture of tissue factor and tissue plasminogen activator; b) incubating the mixture obtained in step a), then adding calcium ions to the mixture obtained, in order to initiate the formation of a fibrin clot; c) measuring the turbidity or the optical density of the clot being formed in step b), at at least two wavelengths of between 450 nm and 850 nm, and for a time of between 1 and 35 minutes; d) determining the structural profile of the analysed clot, expressed as a number of protofibrils, density and radius in c) by means of the formula τ.λ5 = A [Fg].(λ2 - B), wherein τ is the turbidity of the clot at a given wavelength λ, [Fg] is the initial weight concentration of fibrinogen, and A and B are coefficients which are proportional, respectively, to the density and the radius of the fibres that make up the clot; and e) comparing the obtained profile with a control. The method preferably includes a step f) that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.

Classes IPC  ?

• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

Abrégé

A method and device for detecting a worsening of the cardio-respiratory condition of a patient treated using a respiratory assistance device comprising means for collecting and processing parameters indicative: - of a first parameter indicative of the breathing rate in a first observation window; - of a second parameter indicative of the percentage of cycles initiated by the patient during a second observation window; - of a third parameter indicative of the duration of use of the apparatus during a third observation window. The method is characterized in that it involves detecting a significant variation in one of said parameters over at least two consecutive or non-consecutive days during a consecutive period of n days, where n is strictly greater than 3 and preferably greater than or equal to 5; and, in response to said detection, generating an alert intended for said patient or for a practitioner in order to inform same of a significant risk of worsening of the cardio-respiratory condition of the patient.

Classes IPC  ?

• A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The invention relates to a method for the in vitro detection of strains of Legionella pneumophila that are resistant to antibiotics, especially fluoroquinolones. The invention also relates to nucleotide probes and to a kit of reagents allowing the detection of bacterial strains of Legionella pneumophila that are resistant to antibiotics, especially of the fluoroquinolone type.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to pyrrolic derivatives I, processes for their preparation, and their use as new antibacterial drugs.

Classes IPC  ?

• C07D 207/333 - Radicaux substitués par des atomes d'oxygène ou de soufre
• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to a method for dosing the control capacity of plasma serpin (SERine Protease INhibitor) C1 inhibitor (C1Inh) on the basis of a patient blood sample. The invention also relates to a kit specially designed for said dosing.

Classes IPC  ?

• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase

Abrégé

The present invention relates to nanobodies specifically directed against VCAM-1 and to the use thereof in medical imaging and in diagnostic, prognostic and treatment methods.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present patent application relates to a method for diagnosing angioedema with a gain-of-function mutation of kinin formation, and for determining the amount of BK or des-Arg9-BK antagonist required for halting the effects of angioedema, from a plasma sample of a patient. The invention also relates to a kit for said determination.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for predicting and/or diagnosing vascular alterations associated with a disorder in a patient, comprising a step of detecting or quantifying the presence of anti-VE-cadherin autoantibodies in a biological sample obtained from said patient as well as a kit suitable for carrying out such method.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The invention relates to a method for the in vitro diagnosis of a brain tumour belonging to the group consisting of two types of tumours - ODG and GBM - and the identification of the type of tumour, comprising the measurement of the expression levels of at least one first and one second miRNA respectively belonging to two different miRNA groups, in a sample from a patient suspected of having one of said brain tumours.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to a method for the in vitro diagnosis of a brain tumour belonging to the group consisting of two types of tumours - ODG and GBM - and the identification of the type of tumour, comprising the measurement of at least two ratios of the expression levels of miRNA pairs extracted from a biological sample from a patient suspected of having one of said brain tumours.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a device for controlling a blood flow produced in a hemorrhagic area (4) of biological tissue (8), including a flexible plate (2) that is arranged so as to be placed opposite said area (4) and includes: a substantially sealed peripheral bearing means (3) capable of being applied onto the biological tissue (8) while surrounding the hemorrhagic area; a bottom wall (5) that defines, together with the bearing means (3), a hollow space (6) opposite the area (4); a connection means (14, 15) arranged so as to connect the hollow space (6), outside the flexible plate (2), to an outer suction source so as to create, within the hollow space (6), a vacuum for suctioning and tightly applying the surface (7) of the tissue (8) against the peripheral bearing means (3); and a hollow contact pad (11) which is placed between the area (4) and the bottom wall (5), which has a recess in the center thereof on the area (4) side and along an axis (10) substantially perpendicular to the bottom wall, and which is arranged so as to be in contact with the area (4) when the vacuum is created in the space (6).

Classes IPC  ?

• A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
• A61M 27/00 - Appareillage pour drainage des blessures
• A61B 17/30 - Pincettes chirurgicales, c.-à-d. pinces chirurgicales

Abrégé

The present invention relates to a hemostatic device (23) for controlling a blood flow occurring in a hemorrhagic zone (4) located in a hollow component, comprising: - a flexible plate (26) equipped with two opposing faces (27, 28), substantially parallel, said plate comprising an empty internal volume (29) between its two faces, and - connection means (30) linked for connecting the internal volume (29) to suction means external to said device, so as to create a depression in this internal volume (29), said connection means typically comprising a connecting tube (31), each of the faces (27, 28) being equipped with holes (32) that communicate, via these faces (27, 28), the internal volume (29) and the exterior of the plate such that when said depression is created in the internal volume, the suction is applied simultaneously to two opposite walls of the hollow component so as to keep them close together.

Classes IPC  ?

• A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
• A61M 27/00 - Appareillage pour drainage des blessures

Abrégé

The present invention relates to a device for controlling a blood flow produced in a hemorrhagic area (4) of biological tissue (8), including a flexible plate (2) that is arranged so as to be placed opposite said area (4) and includes: a substantially sealed peripheral bearing means (3) capable of being applied onto the biological tissue (8) while surrounding the hemorrhagic area; a bottom wall (5) that defines, together with the bearing means (3), a hollow space (6) opposite the area (4); a connection means (14, 15) arranged so as to connect the hollow space (6), outside the flexible plate (2), to an outer suction source so as to create, within the hollow space (6), a vacuum for suctioning and tightly applying the surface (7) of the tissue (8) against the peripheral bearing means (3); and a hollow contact pad (11) which is placed between the area (4) and the bottom wall (5), which has a recess in the center thereof on the area (4) side and along an axis (10) substantially perpendicular to the bottom wall, and which is arranged so as to be in contact with the area (4) when the vacuum is created in the space (6).

Classes IPC  ?

• A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
• A61M 27/00 - Appareillage pour drainage des blessures
• A61B 17/30 - Pincettes chirurgicales, c.-à-d. pinces chirurgicales

Abrégé

The invention relates to a device for transiently contacting at least one unit for capturing biological targets with a body fluid containing them, a method for recovering the captured targets for analysis, and a system for contacting and recovering a capture substrate included in said unit. The invention relates to samples obtained in particular in vivo from body fluids of the human body, e.g. circulating body fluids, said fluids possibly containing, as targets, proteins, oligonucleotides such as RNA or DNA, antibodies, enzymes or cells. A contacting device (1) according to the invention comprises: - a sampling tip (2) having a contacting end intended to be introduced into a medium containing said fluid, and - the or each capturing unit which is bound to said end and which comprises a capture substrate (3) defining a target capturing surface covered with at least one biocompatible and porous crosslinked polymer layer (4) designed to retain the or each capture substrate and only to allow biological particles including targets smaller than a limiting size to pass through, in such a way that the or each capture substrate is recoverable after said contacting by dissolution of the or each layer.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

The present invention relates to a surgical instrument (1) for sampling molecules from an organ to which access is possible directly or via a surgical approach, including: a device (5) for capturing said molecules, a stylus (4) supporting said capture device (5) and which is capable of penetrating the organ, and a guide (3) for inserting the stylus (4) into the body up to the organ, characterized in that the distal end of the guide (3) is provided with a damping block (6) intended to bear against the organ.

Classes IPC  ?

• A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/34 - TrocartsAiguilles à ponction
• A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)

Abrégé

The invention relates to a device for in vivo dosimetry, consisting of: a miniature probe (1) comprising at least (i) a radioluminescent material (3) which emits a luminescence signal having an intensity that varies according to the high-energy radiation irradiating the material (ii) and an optical fibre (4) which receives the radioluminescence signal and transmits same to a luminescence detection system (14); and a luminescence detection system. The invention is characterised in that the radioluminescent material is gallium nitride (GaN), emitting a luminescence signal in at least one narrowband (BE), and in that the luminescence detection system (14) includes an optical device (18) that can be used to select the gallium nitride emission narrowband.

Classes IPC  ?

• G01T 1/161 - Applications au domaine de la médecine nucléaire, p. ex. comptage in vivo
• G01T 1/20 - Mesure de l'intensité de radiation avec des détecteurs à scintillation